StemCell Therapy

Ageing is inevitable at least for now. As we get older, we become increasingly aware of the importance of healthy life choices to prevent disease and promote wellbeing.

We can do this through good eating and exercise, but we can also enhance our wellbeing with the use of herbs.

HERBS TO HELP DIGESTION

Bitter herbs are useful for digestion. The bitter taste stimulates receptors in our mouth, which increases the production of saliva, gastric juices and bile, all of which contain digestive enzymes to break down our food.

Gentian and yarrow are well known bitter herbs, but those that are more easily accessible to the home gardener are rocket, dandelion greens, endive and radicchio. Eat them in a salad before your meal to aid digestion.

READ MORE:* 5 healing native herbs and how to grow them*The science behind super-herb,mnuka*Kawakawa: herbal healing from the bush*Herbs to help you combat stress & anxiety* 10 reasons to grow sage

ACHIM, DEIMLING-OSTRINSKY/STOCKF

Dandelion, sorrel, rock and watercress.

Hepatic herbs are herbs that aid the liver. Oneof particular value is milk thistle (Silybummarianum), its active constituent beingsilymarin.

Silymarin acts as an antioxidant. Studies have also shown thatsilymarinhas significantly increased the life expectancy of individuals with liver cirrhosis and liver cancer. Silybum marianum is a pest plant in New Zealand, so supplements are necessary, but this herb may be very useful for healthy ageing, as our liver function declines.

To help soothe the stomach, demulcent herbs those rich in mucilage are effective. When infused in cold water, the mucilaginous gel lines the gut and formsa protective film, cushioning it from irritants, reducing muscle spasms, and helping to soothe inflamed tissues. Demulcents are useful for inflammatory conditions such as gastritis, enteritis, ileitis and colitis.

How to make the perfect cup of herbal tea.

Slippery elm, marshmallow root and liquorice are excellent demulcents that soothe the gastrointestinal tract if inflammation is present.

Hoheria, a New Zealand native plant, also acts as a demulcent.

To lower inflammation further, herbs such as chamomile (my favourite) and lemon balm are helpful. These can be made into a tea to be sipped on throughout the day. Slippery elm may decrease the absorption of medications, so take it at least two hours before or after taking medications.

1 of 10FISFRA/123RF

Thyme has an essential oil, thymol, an antiseptic that can help ward off colds and flu, and soothe sore throats. It's also used in commercial mouthwashes. Try thyme for relieving colds, sore throats and coughs as well as to help clear mucus in the upper respiratory tract. It has also long been used to relieve tonsillitis and inflammation of the mouth. Combine it with sage to make a gargle at the first sign of a sore throat or to alleviate coughs. Use 3-12g of dried thyme each day; infuse in freshly boiled water and drink during the day, or use to gargle. In the garden, thyme likes a sunny spot in free-draining soil.

2 of 10LUCIAN MILASAN/123RF

German chamomile is well known for its healing properties. Its gentle nature makes it useful for treating a wide range of childhood complaints, including restlessness, teething and colic. Adults, too, can enjoy a cup of chamomile tea to ease stress, anxiety and irritability. Chamomile has sedative properties, but it's also antibacterial, antifungal, antiviral, anti-inflammatory and antispasmodic. It can be used in salves or compresses to soothe sores, rashes and other skin conditions, or in steam baths to calm nerves, clear congestion, alleviate bronchitis, sinusitis and hayfever. Just steep a handful of dried chamomile in a bowl with boiling water, put your head over the bowl and cover with a towel. In the garden, chamomile prefers an open, sunny area but will grow in part shade. Harvest flowers when just or very nearly opened. If left on the plant too long, they will taste bitter.

3 of 10ZIGZAGMTART/123RF

Peppermint has a wide variety of medicinal uses, but it's especially good for gut and bowel problems as it helps expel gas and stop gas build-up. It's also used to treat headaches, nausea, morning sickness, diarrhoea, and anxiety associated with depression. Make a herbal steam inhalation to help clear congestion and soothe sinus inflammation, or sup on peppermint tea for upset stomach, to aid digestion and ease anxiety. Carry sprigs of peppermint with you when travelling for sniffing, to prevent motion sickness. In the garden, peppermint is a hardy perennial that grows 30-60cm. It spreads by sending out runners, so keep it contained in large pots. Soil should be moist but free-draining. Excess moisture around the root zone can lead to fungal diseases.

4 of 10JITTA/123RF

Lemon balm has mild sedative and mood enhancing properties, and is a common home remedy to treat insomnia, stress, anxiety and depression. It is also traditionally used to ease nausea, settle an upset stomach and relieve gas. Its antiviral properties speed up the healing of cold sores. To make a relaxing tea, loosely pack a teapot with fresh leaves, add boiled water and steep for 10-15 minutes. Drink up to 3 cups a day. Or make a salve as per the instructions above. You can also make a poultice from the fresh leaves to soothe sores, minor cuts and insect bites. In the garden, lemon balm is a perennial that grows 60-80cm, dying down in winter. Plant in moist, free-draining soil in sun or part shade.

5 of 10ANNO GRATYS/123RF

Comfrey has been used for centuries to reduce swelling and bruising, and heal superficial wounds. Also known as knitbone, it was once thought to mend broken bones. It also has anti-inflammatory properties. To make a comfrey poultice for bruises and sprains, pick 6-7 leaves and roughly chop. Use a mortar and pestle to grind the leaves. Add enough boiling water to make a thick paste. Apply directly to the skin or spread the mixture between two layers of cotton or gauze in the size that you want your poultice to be. Apply to the skin. Wrap with cloth. Replace with a fresh poultice after a few hours. In the garden, comfrey will grow in sun or part shade, and any cut or damaged piece of root will regrow. Confine it to one area and dig in plenty of compost or aged manure.

6 of 10CARMEN RIEB/123RF

Calendula is known for its skin-healing properties. It is said to hasten cell growth, so it's seen as ideal for treating infections, abrasions, cuts, rashes, scalds and small wounds. Calendula is also anti-inflammatory, antiseptic and inhibits bleeding. Make a tea from the fresh or dried flowers, then soak a clean cloth in the infusion. Wring it out and place over rashes, scalds or wounds. Or make a salve. Fill a glass jar with calendula flowers (leave them to wilt for 12 hours before using), screw on the lid and put the jar in a warm room out of sunlight for 4-6 weeks. Turn the jar upside down once a day. After 6 weeks, strain. Put 100ml calendula oil and 15g beeswax in the top of a double boiler, and heat gently until the beeswax has melted. Remove from the heat and add 10-20 drops of essential oil (chamomile essential oil is a powerful anti-inflammatory; lavender is antimicrobial and soothes the skin). Pour into small, clean pots. In the garden, calendula likes a sunny spot in free-draining soil.

7 of 10JITTA/123RF

Sage has antifungal and antibacterial properties that have contributed to its reputation as a healing herb. It is used in tonics for sore throats, infected gums and mouth ulcers. To make a gargle, combine sage with a little cider vinegar, or honey and lemon, and steep in boiling water. Historically, sage has also been used as a tonic for the brain, and studies today show it may well be beneficial. British scientists found that sage improved the mood and memory of healthy adults, and adults with mild to moderate Alzheimer's showed significant improvement in cognitive functions after using sage for four months. Sip on sage tea throughout the day to calm the nerves and stimulate the brain -- ideal for those studying for exams. Sage tea is excellent for women suffering from night sweats and hot flushes too. Combine it with alfalfa (Medicago sativa) for a potent remedy. Studies have shown the two herbs are extremely effective together. In the garden, sage likes a sunny spot in free-draining soil. Water young plants frequently until established.

8 of 10JIRI VACLAVEK/123RF

Mullein is said to be antibacterial, anodyne (relieves pain) and anti-inflammatory. Mullein leaves can be used to treat coughs. They contain mucilage, which acts as an expectorant and soothes irritated mucous membranes. Harvest leaves before the flower stems appear, bruise slightly and steep in boiled water for 10 minutes. You can also try a steam bath and inhale the steam to relieve congestion. In the garden, mullein is a biennial. It produces flowers in its second year.

9 of 10MADLLEN/123RF

Yarrow has antiseptic, anti-inflammatory, antimicrobial and antispasmodic properties. It has traditionally been used to staunch bleeding, reduce fevers (it opens your pores and induces perspiration) as well as ease tight muscles and spasms. To help stop bleeding, grab a handful of leaves, rub them to release their juice and pack onto minor cuts. Or make a tea from the fresh or dried plant, soak a clean cloth in the infusion, wring it out, and put over the wound. To stop a bleeding nose, insert a bruised leaf into the nostril. When ingested, yarrow is said to help alleviate indigestion as well as stimulate bile flow and liver function. Take it at the first sign of a cold. Yarrow has astringent properties, and may help dry up and expel mucus from the respiratory system, as well as reduce inflammation in the nose and throat. To keep yarrow on hand all year round, dry leaves and flowers, and grind to a powder. In the garden, yarrow loves a sunny spot in well-drained soil.

10 of 10INGA TIHONOVA/123RF

Aloe vera is used in its raw form to treat burns, bites, blisters, cuts, ulcers, inflammation, rashes, eczema and psoriasis. The gel within the plant contains bradykinase, salicylic acid and magnesium lactate, which help reduce inflammation, pain and itching. The gel is also said to speed up wound healing, promote cell and tissue regeneration. The easiest way to use it at home is to slice open a leaf and rub the gel onto minor burns, sunburn and cuts. However, when exposed to oxygen for prolonged periods, the gel oxidises (much like an apple browns when the flesh is exposed to air) and loses its potency. Use the gel within 2-4 hours after cutting. If you only require a small amount of gel, just cut off what you need. If you've cut a whole leaf from the plant but only use a small amount, snip off what you need from the leaf and wrap the rest in clingfilm and store in the refrigerator. When it comes to using it again, cut the used end back to the undamaged tissue, then cut off another piece to use. Harvest leaves from plant that are at least three years old as the active constituents are higher in mature plants. In the garden, grow aloe in sun and protect from frosts.

CARDIO-FRIENDLY HERBS

The risk of heart disease rises with age. While herbs cannot replace fast-acting, life-saving pharmaceuticals, they may be beneficial for many of the chronic degenerative conditions that are associated with ageing.

Cardiotonic herbs are helpful. In herbal medicine, hawthorn is the number one herb for cardiovascular ailments, with the leaves, flowers and fruit all being used. Hawthorn contains powerful antioxidants, and these antioxidants may help dilate blood vessels, improve blood flow and protect coronary arteries from damage.

Studies suggest that hawthorn may help sufferersof angina, which is caused by reduced blood flow to the heart. Most studied are Crataegus oxyacantha, Crataegus monogyna and Crataegus laevigata. Crataegus oxyacantha is one of the two species medicinally recognised in European Pharmacopoeia (which provides reference standards for medicines in the continent) and is used in the treatment of numerous heart conditions, including hypertension, atherosclerosis, angina and abnormal cardiac rhythms.

If you can find a hawthorn plant with berries (they fruit in late summer to autumn), pick and dry them and use them to make a simple tea. Alternatively, use the leaves and flowers.

To make a tea, infuse up to a 1.5 to 3.5gof dried berry, leaf or flower a day (people with heart conditions who are taking medication should consult their doctor first).

HERBS TO BOOST YOUR IMMUNE SYSTEM

The older we get, the more susceptible we become to disease and infection. This is because the immune system, a network of cells, tissues and organs that work together to shield the body from attacks from a hostof organisms, declines in function as we age. This has the potential to generate several problems.

One such problem is the clearing away of senescent cells in the body. Senescent cells are cells that have stopped dividing but refuse to die despite programmed cell death. A function of the immune system is to hoover up these cells; if they remain behind, they cause chronic inflammation and accelerated ageing. As we get older,this process is compromised.

Enter Astragalus membranaceus. One of the mostpopular herbs in traditional Chinese medicine, it's used for a variety of purposes, including immunoregulation the control of immune responses between lymphocytes and macrophages (macrophages clean up senescent cells). But it also has anti-inflammatory, antioxidant, antihyperglycemic, anticancer and hepatoprotective (protects the liver from damage) properties, and can increase telomerase, an enzyme that extends the telomeres of chromosomes (longer telomeres are good; shorter telomeres are associated with ageing).

So as far as beneficial herbs for ageing go, astragalusis a superstar. You can make a tincture of the dried roots or use it in teas.

And the great news is, Kings Seeds now sell astragalus seeds. This hardy plant grows best in well-drained soilin full sun. Harvest the roots in autumn after three years.

There are many herbs that support healthy ageing.Take the opportunity to explore their usefulness, and then, if you can, grow them in your own backyard so you can make use of them easily.

Go here to see the original:
Herbs to aid digestion, heart health & immune system - Stuff.co.nz

One of the most common health challenges of our time ischronic stress, which, we know can cause, or play a major role in the development of chronic disease. In the midst of multiple demands in todays world, and the fast pace of life, its hard not to be in the fight or flight mode most of the time. We all feel the weight of the stress of work, family, health, social stressors, or unexpected events. The process of evolution hasnt yet caught up to the fast- changing world of multitasking, the speed with which we communicate, make decisions and create and execute our to-do lists. Its hard to be present and appreciate the moment. While naturally programmed to seek security and control, its hard for us not to worry about things that are uncertain (read: everything in life!).

It is no surprise that the U.S. adult population reports significant levels of stress about the future, finances, healthcareto name a few examplesin recent surveys of theAmerican Psychological Association.

We cannot control the outside world, but we CAN CONTROL how we RESPOND to it.

Here are simple, yet powerful tips of how you can cultivate a practice of mindful responsiveness and awareness, rather than be in a loop of never-ending stress, worries and negative thinking.

Whether meditation is new for you, or has been something youve tried but couldnt do, I invite you to view it with a beginners mind. Allow yourself to be patient even when those thoughts are racing, and you are not paying attention to your breath, mantra, or the object of your meditation. A key aspect of the practice of meditation is that we feel acceptance of discomfort, boredom or distraction. This acceptance will lead to a sense of comfort (even with discomfort!) and greater ease with which we practice, which will lead to a more consistent practice. The results are limitless and can range fromimproved moodin individuals with depression,better sleep, andless chronic pain. Beware, consistent practice can also lead to a complete mind and body transformation and a more optimistic outlook on life!

Here are some ofmy favorite meditation resources:

In order to realize our full potential and ease our bodies into the healing mode, it is necessary that we turn down the always on fight or flight mechanism, and activate our parasympathetic nervous system. Regular mindfulness and meditation practice will help with this.

I hope that as you create your own mindfulness journey, you let your inner beauty, love and compassion shine, and that you illuminate this world with kindness and wisdom that are more powerful than ever. I trust that you will find more peace and more ease, as you follow the steps here. Keep me posted on your journey!

Namaste,Dr. Bojana

*This article originally appeared on http://www.drbojana.com

See the original post:
How to reduce your stress and thrive, starting today! - Thrive Global

STATEN ISLAND -- With as many as 5,000 problem gamblers around the Island, the Gamblers Treatment Program at Richmond University Medical Center officially expanded to a new headquarters Friday.

Local elected officials, doctors from RUMC and representatives from the state and city cut the ribbon at the programs new headquarters at RUMCs Center for Integrative Behavioral Medicine at 1130 South Ave. in Bloomfield.

One of our main purposes was to bring this program and this type of program closer to the community and take it out from behind the black wall, from behind closed doors and make sure that those folks who are suffering from this addiction and other addictions and other behavioral health disorders do not feel embarrassed, said Rosemarie Stazzone, RUMCs chief operating officer and chief nursing officer.

RUMCs problem gamblers program launched in 1982 as one of three outpatient gambling programs in the state and currently serves as one of the only programs of its kind in New York City.

As gambling becomes more accessible over the Internet and on cell phones, officials said gambling is targeting the Islands youth in particular.

The accessibility to all forms of gambling has increased with the Internet, with legislative changes, with casinos, and gambling and the close proximity to Atlantic City, its certainly a great temptation for problem gamblers to continue their addiction or regress from breaking away from their addiction," said Dr. Daniel Messina, RUMCs president and CEO.

Messina said of the 5,000 gamblers around the Island, many of them are not enrolled in any kind of treatment program.

Dr. Joel Idowu, who chairs RUMCs Department of Psychiatry and Behavioral Health, said gambling is an up and coming epidemic in the field of psychiatry and mental health and affects more men than women.

FOLLOW SYDNEY KASHIWAGI ON TWITTER.

See the rest here:
RUMC expands its gambling treatment center to new Bloomfield headquarters - SILive.com

The Cottage Sexual Assault Center & Children's Advocacy Center is hosting today its sixth annual Unplugged for the Cottage fundraiser.

The Cottage educates to prevent sexual violence and child sexual abuse and provides in-house therapy to those who have survived it. They help survivors pay for referrals to other therapeutic resources when it is necessary.

The Cottage Sexual Assault Center & Children's Advocacy Center hopes that Unplugged for the Cottage will raise awareness about their cause and $10,000 to provide therapy to children and adults who have survived sexual abuse and assault.

It began as a music event for local musicians to show their support for our mission, said Sally Kimel-Sheppard, the executive director of The Cottage Sexual Assault Center & Children's Advocacy Center. We had a board member who knows a good bit of the local musicians here and she thought it would be a great idea for us to have a gathering where musicians who support the cause could come together and play acoustically.

This year, Caroline Aiken, Athens Tiny Jazz Arkestra, Betsy Franck and Diet Dangfly will perform. Kimel-Shepard says that the music is her favorite part because it is uplifting.

Mama's Boy, Ike & Jane, Sweetie Pie by Savie and several others will provide food for the event. Lori Karr will be recognized for working with The Cottage for 10 years.

There will be a silent auction, a donate-to-win and a cork pull. Most of the prizes for all of the activities are from local businesses because The Cottage wanted to make this event about the community.

Its a local event celebrating our communitys support of child abuse and sexual assault intervention that is done by the cottage, said Kimel-Sheppard.

Guests can donate for a chance to win a handmade wine rack, a Sarah Cook Painting or a pet portrait by Rebecca Pearson. The cost is $10 for one chance to win or three chances for $25.

In the silent auction, guests can bid on Art by David Hale, rounds of golf at the University of Georgia Golf Course and Athens Country Club, a basket from Thrive Integrative Medicine, a basket from Jittery Joes and more. Those who are not interested in those prizes can participate in the cork pull and try to win wine and spirits.

Winners of the silent auction and donate-to-win will be chosen the night of the event.

Unplugged for the Cottage will take place at Little Kings Shuffle Club from 6-9 p.m. Tickets are $25 and can be bought at the door or at northgeorgiacottage.org.

See the original post:
Unplugged fundraiser benefits The Cottage - Bluffton Today

The Veterans Administration has traditionally been an incubator for innovations that improve quality of life not only for veterans but also for civilian populations around the worldideas like bar-coding machines, or the discovery that daily aspirin cuts the rate of heart attacks for certain patient populations. For many years and in a range of capacities, Penns School of Nursing has been a close VA collaborator.

In 2011,for example, in addition to her role at Penn, palliative care professor Mary Ersek became director of the Veteran Experience Center, a national quality-improvement initiative housed at Philadelphias Corporal Michael J. Crescenz VA Medical Center. Rosemary Polomano, Penn Nursings associate dean for practice and a professor of pain practice, helped change the standard pain scale employed by the VA.

There are many examples of this partnership, with innovative solutions aimed at the largest integrated health system in the U.S. and the top employer of nurse practitioners, according to the Veterans Health Administration. Along the way, the VA has also built systems for tracking outcomes, leading to a treasure trove of data.

Its a great time for evidence-based research and training, saysCoy Smith, associate director of patient care services and nurse executive at the Philadelphia VA, as well as assistant dean for clinical practice at Penn Nursing. A lot of this work is transferrable to non-VA patients.

Here, a look at the work made possible because of the Veterans Health Administration-Penn Nursing collaboration.

Evidence-based health care practices are interventions based on the best, latest scientific findings. Penn sleep and health behavior researcher Amy Sawyer is currently leading 15 evidence-based quality improvement projects at the Philadelphia VA, on subjects like preventing injury in surgical patients and secondary traumatic stress in health care providers.

Change, no matter how you look at it, is hard, Sawyer says. Its hard to accept, and its hard to convey to others that change needs to happen. But implementing it can have real results, like with a recent occupational health project that involved switching the type of tuberculosis testing the VA used for incoming employees.

Unlike the standard test, called purified protein derivative or PPD, a newer test called T-SPOT.TB does not require a follow-up visit after 48 to 72 hours. During a PPD shortage two years ago, VA clinicians put in place the T-SPOT.TB procedure and followed it for a year. The program has since rolled out across the entire VA system, leading to a 29% increase in employee compliance, a 40% drop in costs, and a 50% reduction in time to clear new hires.

We used to think of quality improvement and research as separate, Ersek says. But over the years weve gotten more sophisticated. We use research methods. We sort of mimic, statistically, a randomized control trial.

To that end, Ersek and her team use the Bereaved Family Survey (BFS) in their VA work. The BFS, developed through a VA-funded research project and now used throughout the system, asks respondents to evaluate quality of care at the end of life. Its mailed to the next of kin of every veteran who dies at a VA facility or in one of several VA home-based primary care programs. Facility-level scores are calculated quarterly and sent to each facility. The Veteran Experience Center also works directly with care teams to help them interpret their scores and develop strategies to improve care and outcomes.

For example, we might identify chronically low scores on an overall item, as well as those related to communication for a specific facility, Ersek says. Training in family conferences might then follow. We continue to monitor their BFS scores during and following the training to see whether it had an impact on outcomes, she adds.

The survey is a unique way to keep a pulse on the quality of care at the VA for veterans and families, saysAnn Kutney-Lee, an adjunct associate professor of nursing who studies the effects of nursing care organizations on patient outcomes. We ask about communication with providers, whether their preferences were met for treatment, she says. We ask about emotional and spiritual support. Did they get the amount of support they wanted? Did they see a chaplain if they wanted one?

Veteran demographics are shifting from those who served in World War II and the Korean War to those who served in Vietnam. This has implications for end-of-life care, as veterans from the Vietnam era are more likely to have been exposed to dangerous combat situations, says Kutney-Lee. Many veterans were fighting in jungles and mountains; there were hidden explosives planted, all with a near-constant threat of being ambushed, she says. The nature of the direct combat situations was very different.

The way society welcomed them home was different, too. World War II vets were hailed as heroes, enjoying national support. Vietnam vets experienced the opposite, says Kutney-Lee. Things were thrown at them when they got off the planes. Today, they are less willing to talk about their experiences, something that can resurface, emotionally, at the end of life.

Its something Kutney-Lee and colleagues are trying to understand to better prepare health care providers to treat these vets. They are seeing higher rates of anxiety and post-traumatic stress, as well as more chronic illnesses that correlate with chemicals such as 2,4,5-T, an ingredient in the herbicide Agent Orange, to which many soldiers in Vietnam were exposed. In an effort to be proactive, the VAs Hospice and Palliative Care Program Office and the Veteran Experience Center are using the BFS and other data to create educational programs aimed at helping providers meet this groups unique end-of-life needs. We want the vets and their families experience to be as peaceful as possible, Kutney-Lee says.

She is involved in another project with Ersek andMargo Brooks Carthon, another Penn Nursing researcher, to study racial and ethnic disparities in quality end-of-life care for vets. Some of their work has found that the next of kin of African American vets were 50% less likely than other groups to report that their loved ones received excellent care at the end of life. The researchers want to know why.

One clue: Members of racial and ethnic minorities tend to be more sensitive to changes in nurse-staffing levels. The researchers hypothesize that in facilities where staffing is better, nurses are better positioned to meet the complex care needs of patients, which may also apply at the end of life. They have the resources they need and the time to spend with their patients, says Kutney-Lee.

Pain management entails a complex matrix of mind and body, which makes having a standard scale on which to measure pain crucial.

Penn Nursings Rosemary Polomano specializes in managing acute pain following combat-related injuries. After learning that clinicians in 28 facilities who used the standard numeric pain rating scale (0-10) found it inadequate to help patients and health care providers communicate about pain-intensity levels, Polomano collaborated with leaders from the Defense and Veterans Center for Integrative Pain Management and others to develop the Defense and Veterans Pain Rating Scale (DVPRS).

The scale integrates word anchors (from no pain to as bad as it could be, nothing else matters) with color-coding and facial expressions to help patients rate their pain.

According to Polomano, DVPRS is now the official military pain scale, with the goal of being used in all Department of Defense health care facilities. Other health systems are free to use it too, Polomano says. It is in the public domain.

Polomano also teachesPain Science and Practice, a class open to students from Penn Nursing, Penn Dental, and Penns Perelman School of Medicine. This year, in partnership with the Uniformed Services University Graduate School of Nursing in Bethesda, Maryland, 30 active-duty military personnel from their nurse anesthesia program attended the class.

Nurses work at the heart of the changes in veterans care and, therefore, help to shape the future of American health care. Much of the VAs innovative models of care delivery are due to the leadership and contributions of VA nurses, says David Shulkin, a Distinguished Health Policy Fellow at Penns Leonard Davis Institute of Health Economics and a former secretary of veterans affairs. Its often their affiliation with leading academic centers like Penn that help to ensure the VA remains at the forefront of these innovations.

Ive often felt that the VA is the best place for advanced practice nurses, saysPatricia DAntonio, the Carol E. Ware Professor in Mental Health Nursing and director of the Barbara Bates Center for the Study of the History of Nursing. One of the best jobs she says she ever had was working with VA nurses to identify and help patients with compelling emotional or psychological needs. One patient, an outgoing, lovable former boxer, would sometimes lash out and punch someone when he got upset. The VA nurses developed a plan to appoint him an unofficial nursing assistant. He followed a nurse around, carried water, etc. He had a job to do, says DAntonio. With a new sense of purpose, he could control his anger. No more punching.

Ersek was similarly drawn to the VAs work. Being involved in the military, thats a big honor. Our mission as care providers is not about prestige, she says. We get to use rigorous research methods, but I like that we stop and say its not just an academic exercise; its about using these advanced analytic methods to improve care for veterans.

That sense of purpose goes a long way. I havent practiced clinically at the VA since 1992, says DAntonio, but I still describe myself as a VA nurse. Its part of my identity. Thats true for many among the ranks of Penn Nursing faculty, who work hand in hand with the nations largest integrated care system treating a unique patient population thats changing every day.

A longer version of this feature, by Louis Greenstein, originally ran in the Spring 2019 issue of the Penn Nursing Magazine.

Follow this link:
Working hand in hand with the nation's largest integrated care system - Penn: Office of University Communications

Recently, World Health Organisation (WHO) pledged support to the federal government to integrate traditional medicine into national healthcare, what is your take on this?That is hugely awesome and no doubt it is an encouragement for practitioners of traditional medicine that the days of more honour and recognition for our practice is here. As it is said, the future is here. With this kind of support from the global apex health body, it further goes to show that the world knows and confirms that indeed nature cures. Of course, this is not the first time we would be telling the masses that nature has cure for all that affects our body, but this kind of recognition speaks volume to the wide acceptability of our call. In no time, we would begin to see even medical doctors rallying around traditional medicine for integrative treatment for ailments just as we have seen in other climes where the practice of natural medicine has been more established and controlled. Even as natural therapies continues to bask in the glory of its richness and wellness as an efficient cure system, this kind of support at this time in our country is needed to harness all the potentials. We look forward to seeing in practice and learning of this healthcare system, which we believe will fight against incompetence and lack of best practice that ravages the traditional medicine.

What is the likely outcome of this synergy?If by this you mean the synergy the integration of traditional medicine into the healthcare system will birth, then one thing I would say is, let us look at the Chinese and the Indians. What did the synergy foster for them? A sustainable healthcare system, assured healthy living and a population living more hale and hearty. This is because with traditional medicine and implementation of best practice which is a function of structured learning, just as we have for the orthodox medicine, will not just treat the surface of ailments or treat the effects of diseases, rather traditional medicine will imbibe the very message of natural treatment therapies which is to treat the root cause of every diseases and create true cure for the body. As abundantly blessed as the Nigeria has been blessed with almost all kinds of herbal and other traditional medicine therapies, we are yet to harness this into both health wellness and economic growth. The reason for this being that there are a lot of quacks in the practice of traditional medicines.

But with a synergy like this, it will bring forth more standard which will enable us to sieve the shaft away from the substance, making the business of health primarily based not on making money but that of saving lives and empathising with those with ailments of different kinds. Lastly, with a synergy like this, we would find standards in our traditional healthcare management system just as I saw in my recent travel to Malaysia for an International Course on Neuroacupuncture and Non Invasive Pain and Paralysis Management.

How do you think traditional medicine can fit into healthcare?Traditional medicine, which is primarily about utilising nature in the process of administering cure, is synonymous to effective healthcare just as life is synonymous to living. Any healthcare system that is yet to embrace traditional medicine as a mode of treatment is not only lagging behind, it is almost nonexistent because the very basis upon which living is formed, that is nature, has been neglected. I remembered when I was learning at the Indian Board of Alternative Medicine where I first bagged my Doctor of Natural Medicine after having graduated from University of Ilorin as a first degree holder in Biochemistry, my learning made it clear that even the synthetic drugs used in curing humans has a greater element of natural cure in it. Why then would someone not want to go to natural cure through expert guidance and make-up to cure that which affects the body.

You have had success in treating patients with chronic and severe pain within few minutes, what can you say about this?We as doctors are only applying treatment protocols with best practice, we cannot totally lay claims to our knowledge and practice as the basis for the success. God Almighty cures and no doubt about that. But then as humanly possible, yes, it is true that I am having success in treating chronic pain related ailments such as sciatica, paralysis patients and so on and within minutes, my patient experience instant relief from pains they have suffered in years. In fact, my teacher that taught me this treatment system would treat over 200 patients in a day when I was learning with him. These are patients with different chronic pain and paralysis related health issues. So, the treatment methodology I employed is Non-Invasive Neuroacupuncture which I learnt during my last learning tour to Kuala Lumpur, Malaysia. One thing I am passionate about is to continue to research and learn the best and less troubling ways to bring smile to the faces of my patients. This is why aside from putting a lot of efforts into research; I have interest in continuous learning which has made me travel to Colombo, Sri-Lanka where I bagged my Doctor of Medicine in Acupuncture. Still, I am not stopping. My aim is also to bridge calibre in Traditional African and Chinese Medicine to give pristine admiration to natural healing.

How does neuro acupuncture work? Arent there side effects of this therapy?No. Neuroacupuncture is a very good treatment procedure with no known side effects. This treatment is based on knowledge of traditional acupuncture and neurology. It is done by inserting acupuncture needles into loose areolar tissue layer of the scalp to stimulate the brain neurons of the underlying area. Since the skull protects the brain and there are no organs in the scalp to injure it is a very safe treatment. Its a non-invasive procedure and works by stimulating the brain cells that are related to the impaired functions. The mechanism is three-fold: to wake-up the brain cells that are not dead but lacking in proper functioning, to encourage the recruitment of healthy brain cells to perform the lost function and to promote a healthy reintegration of the brain system. It does not only treats pains but also paralysis, Parkinsons Disease, multiple sclerosis, traumatic brain injury, spinal cord injury, motor neuron diseases, Alzheimers disease, restless leg syndrome and attention deficit hyperactivity disorder and other neurological issues. Scalp acupuncture can help regain speech in all kinds of Aphasia: expressive, receptive, anomic or global. The speed and amount of recovery vary with the individual and the severity of damage but progress is usually readily seen within few minutes of treatment.

You treat people with cancer and other chronic diseases, is it only acupuncture that you are using or there is another treatment method you are adopting?First thing I will say here to clarify the misconceptions that there are some incurable diseases is that which I have said in past interviews. I as a person do not believe there are incurable diseases, but I know for sure that there may be incurable cases. So this has influenced my belief and interest in always researching on how we can improve on treatment because people are out there in pains and need healing. Why then would we not as practitioners continue to make research on how to improve the wellness of the people. So going back to the question, no, it is not Acupuncture alone that we use as the treatment protocol. We utilise a system called integrative system that allows us to use different therapies in treating our cancer patients. But then Acupuncture is an integral part of that protocol because it helps us manage pain for our cancer patients. We integrate different therapies in order to achieve success as early as possible. Our local herbs and spices play major role in treating these conditions, also, massage, diet and nutrition therapies. I combine as many therapies as possible. For cancer, up-to seven therapies will be combined depending on the type of cancer. I hold that not any therapy is self-sufficient. Every therapy has its own limitations. Combining them will bring meaningful results and may lead to cure in maturation of time.

Visit to your centre shows some children affected by Autism recovering fast, how do you manage to achieve this?Yes, we have really worked on autism and sincerely I would say that we can assist autistic children get better. We have been successful in about three cases and many more successes are approaching by Gods grace. The major treatment methods are herbalism and neuro acupuncture. Also, administration of Camels milk, black seed and natural honey have really been effective in alleviating the symptoms associated with autistic especially speech difficulty and walking. We appeal that the WHO and FG continue looking into traditional medicine. No doubt, there is a need for integrative medicine in order to achieve better results.

You have treated many HIV patients, but not many are too keen to face the media due to the stigma attached to it, what are you doing differently?Should I say its not curable so that I wont get held? Well, let me simply say the truth. There is no diseases that isnt curable if given integrative natural approach and enough treatment durations. HIV is one of the easiest diseases to treat but unfortunately many still believe its cure is just a claim. There are natural herbs and spices that get rid of this virus in the body within few months, no doubt. Some of what I use are garlic, Indian costus and black seed. They are very potent and give good result if taken for many months. How to prepare, required dose and dosages for different individuals is key and thats where I come in.

See more here:
Medical doctors will soon rally traditional medicine for integrative treatment of ailments - Guardian

A new study published today [Wednesday 6 November] in Psychological Medicine and led by University of Bristol researchers has found that tobacco smoking may increase your risk of developing depression and schizophrenia.

It is well-known that smoking is much more common amongst people with mental illness especially depression and schizophrenia. However, most studies that have looked at this association have not been able to disentangle whether this is a cause-and-effect relationship, and if so in which direction. Does mental illness increase the likelihood of smoking, or is smoking itself a risk factor for mental illness?

Researchers from the University's Tobacco and Alcohol Research Group (TARG) with support from Bristol's MRC Integrative Epidemiology Unit (IEU) and the NIHR Bristol Biomedical Research Centre (BRC), used UK Biobank data from 462,690 individuals of European ancestry, comprising eight per cent current smokers and 22 per cent former smokers.

The team applied an analytic approach called Mendelian randomisation, which uses genetic variants associated with an exposure (e.g. smoking) to support stronger conclusions about cause-and-effect relationships. They found evidence that tobacco smoking increased risk of depression and schizophrenia, but also that depression and schizophrenia increase the likelihood of smoking (although the evidence was weaker in this direction for schizophrenia).

The study adds to a growing body of work suggesting that smoking can have adverse effects on mental health. The same group published a similar study in British Journal of Psychiatry earlier this year in collaboration with the University of Amsterdam, showing evidence that tobacco smoking increases the risk of bipolar disorder.

The UK government's mental health task force made the recommendation in their 2016 review that psychiatric hospitals should be smoke free by 2018. This new evidence adds further weight to support the implementation of smoke-free policies. Not only is there evidence that smoking can be detrimental for mental health, but much of the excess mortality associated with mental illness is due to smoking.

Dr Robyn Wootton, Senior Research Associate in the School of Psychological Science and the study's lead author, said: "Individuals with mental illness are often overlooked in our efforts to reduce smoking prevalence, leading to health inequalities. Our work shows that we should be making every effort to prevent smoking initiation and encourage smoking cessation because of the consequences to mental health as well as physical health."

Marcus Munaf, Professor of Biological Psychology in Bristol's School of Psychological Science and senior author on the study, added: "The increasing availability of genetic data in large studies, together with the identification of genetic variants associated with a range of behaviours and health outcomes, is transforming our ability to use techniques such as Mendelian randomisation to understand causal pathways. What this shows is that genetic studies can tell us as much about environmental influences in this case the effects of smoking on mental health as about underlying biology."

Paper

'Evidence for causal effects of lifetime smoking on risk for depression and schizophrenia: A Mendelian randomisation study' by Robyn Wotton, Marcus Munaf et al in Psychological Medicine [open access]

About the Tobacco and Alcohol Research Group (TARG)TARG conduct research into the psychological and biological factors underlying health behaviours. We are part of the MRC Integrative Epidemiology Unit (MRC IEU) at the University of Bristol.

About UK BiobankUK Biobank is a major national and international health resource, and a registered charity in its own right with the aim of improving the prevention, diagnosis and treatment of a wide range of serious and life-threatening illnesses including cancer, heart diseases, stroke, diabetes, arthritis, osteoporosis, eye disorders, depression and forms of dementia. UK Biobank recruited 500,000 people aged between 40-69 years in 2006-2010 from across the country to take part in this project. They have undergone measures, provided blood, urine and saliva samples for future analysis, detailed information about themselves and agreed to have their health followed. Over many years this will build into a powerful resource to help scientists discover why some people develop particular diseases and others do not.

About the National Institute for Health Research (NIHR)The National Institute for Health Research (NIHR) is the nation's largest funder of health and care research. The NIHR:

The NIHR was established in 2006 to improve the health and wealth of the nation through research, and is funded by the Department of Health and Social Care. In addition to its national role, the NIHR supports applied health research for the direct and primary benefit of people in low- and middle-income countries, using UK aid from the UK government.

About NIHR Bristol BRCThe research centre, awarded to University Hospitals Bristol NHS Foundation Trust (UH Bristol) and the University of Bristol by the NIHR, conducts cutting-edge research to develop new, ground-breaking treatments, diagnostics, prevention and care for patients in a wide range of diseases.

Led by John Iredale (Bristol Pro Vice Chancellor for Health) and Jonathan Sterne, NIHR Bristol BRC has research themes on Cardiovascular Research (led by Gianni Angelini) Nutrition, Diet and Lifestyle (led by Andy Ness), Mental Health (led by David Gunnell), Perinatal and Reproductive Health (led by Debbie Lawlor) and Surgical Innovation (led by Jane Blazeby). The research themes are underpinned by cross-cutting themes in Translational Population Science (led by George Davey Smith) and Biostatistics, Evidence Synthesis and Informatics (led by Jonathan Sterne).

A strand of population health science runs through all themes of the BRC, with a focus on translating scientific discoveries that have arisen from population science into better care for NHS patients.

About the MRC Integrative Epidemiology UnitThe Medical Research Council Integrative Epidemiology Unit at the University of Bristol (IEU) is one of the MRCs flagship University Units. The IEU brings together an innovative collection of research programmes and cross-cutting themes, underpinned by core research activities that will collectively fuel a step-change in causal analysis and their application. The aim of the MRC IEU is to apply the novel causal methods developed in the IEU to key research questions related to causes of bone, cardiometabolic, reproductive, mental and other aspects of ill-health; and to ensure that the results from these studies are appropriately translated into clinical/public health practice and industrial partnerships. A major focus of IEU activities is the integration of omic measures (genomic, epigenomic, transcriptomic and metabolomic) into epidemiological investigations.

Follow this link:
November: Smoking and mental illness | News - University of Bristol

NEW YORK, Nov. 7, 2019 /PRNewswire/ --

INTRODUCTIONAdvances in the fields of cell biology and regenerative medicine have led to the development of a variety of stem cell-based therapies for many cardiovascular, oncological, metabolic and musculoskeletal disorders. Driven by the revenues generated from stem cell therapies, the regenerative medicine market is anticipated to generate revenues worth USD 100 billion by 2030. With a promising pipeline of over 200 stem cell therapy candidates, it has become essential for developers to scale up the production of such therapeutic interventions. Given that stem cell therapy manufacturing requires highly regulated, state-of-the-art technologies, it is difficult for stakeholders to establish in-house expertise for large-scale manufacturing of stem cell therapies. As a result, stem cell therapy developers have begun outsourcing their manufacturing operations to contract manufacturing organizations (CMOs). Specifically, small and mid-sized players in this sector tend to outsource a substantial proportion of clinical and commercial-scale manufacturing processes to contract service providers. In addition, even big pharma players, with established in-house capabilities, are gradually entering into long-term business relationships with CMOs in order to optimize resource utilization and manage costs.

Read the full report: https://www.reportlinker.com/p05826166/?utm_source=PRN

According to a recent Nice Insight CDMO survey, about 55% of 700 respondents claimed to have collaborated with a contract service provider for clinical and commercial-scale product development requirements. Considering the prevalent trends, we believe that the stem cell therapy manufacturing market is poised to grow at a steady pace, driven by a robust pipeline of therapy candidates and technological advances aimed at mitigating challenges posed by conventional methods of production. Amidst tough competition, the availability of cutting-edge tools and technologies has emerged as a differentiating factor and is likely to grant a competitive advantage to certain CMOs over other players in the industry.

SCOPE OF THE REPORTThe "Stem Cell Therapies Contract Manufacturing Market, 2019 2030" report features an extensive study on contract service providers engaged in the development and manufacturing of stem cell therapies. The study features in-depth analyses, highlighting the capabilities of various stem cell therapy CMOs. Amongst other elements, the report includes:

A detailed review of the contract manufacturing landscape for stem cell therapies, featuring a comprehensive list of active CMOs and analysis based on a number of parameters, such as year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). An elaborate discussion of the various guidelines laid down by regulatory bodies related to stem cells and other cell-based therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Elaborate profiles of the key players based in North America, Europe and Asia-Pacific that have a diverse range of capabilities for the development, manufacturing and packaging of stem cell therapies. Each profile includes an overview of the company, its financial performance (if available), information on service portfolio, stem cell therapy manufacturing facilities, and details on partnerships, recent developments and an informed future outlook. An analysis of the recent collaborations (signed since 2015) focused on the contract manufacturing of stem cell therapies, based on various parameters, such as year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. An informed estimate of the annual demand for stem cell therapies in terms of area (in square feet) dedicated to stem-cell related operations, based on various parameters, such as target patient population, price of the therapy, dosing frequency and dose strength. A detailed capacity analysis, taking into consideration the manufacturing capacities of various stakeholders (small-sized, mid-sized and large CMOs) in the market, based on data gathered via secondary and primary research. It also provides the distribution of global stem cell therapy manufacturing capacity by company size (small-sized, mid-sized and large), and geography (North America, Europe and Asia-Pacific) and scale of operation (preclinical / clinical and commercial). A detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. An analysis to identify the key performance indicators for service providers active in the domain, based on the information gathered via secondary research and primary research.

One of the key objectives of the report was to estimate the future size of the market. Based on parameters, such as increase in number of clinical studies, target patient population, anticipated adoption of stem cell therapies and expected variation in manufacturing costs, we have provided an informed estimate of the likely evolution of the market in the mid to long term, for the period 2019-2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world). To account for the uncertainties associated with the manufacturing of stem cell therapies and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders:

Arik Hasson, Executive VP Research and Development, Kadimastem Brian Dattilo Manager of Business Development, Waisman Biomanufacturing David Mckenna, Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota Fiona Bellot, Business Development Manager, Roslin Cell Therapies Gilles Devillers, General Manager, Bio Elpida Mathilde Girard, Department Leader, Cell Therapy Innovation and Development, YposKesi

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

RESEARCH METHODOLOGYThe data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include Annual reports Investor presentations SEC filings Industry databases News releases from company websites Government policy documents Industry analysts' views

While the focus has been on forecasting the market till 2030, the report also provides our independent view on various technological and non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.

CHAPTER OUTLINESChapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the likely evolution of the stem cell therapy contract manufacturing market in the mid to long term.

Chapter 3 provides a brief introduction to the basic concepts related to stem cell therapies and the intricacies of their development and administration. In addition, it includes information on the various types of stem cell therapies (based on the source, potency and lineage of stem cells), modes of delivery and the disease indications targeted by such interventions. It also includes a discussion on the different manufacturing models (centralized and decentralized) that are used for the production of stem cell therapies, along with a list of advantages and disadvantages. Further, it provides details on the scalability of stem cell therapies. The chapter also includes a brief overview on the role of automation and supply chain management, with respect to stem cell therapies.

Chapter 4 provides a comprehensive overview of the global stem cell therapy contract manufacturing landscape. It includes information related to over 80 CMOs that are currently active in this domain. In addition, it features an in-depth analysis of the market, based on a number of parameters, such as the year of establishment, company size, geographical location, number of stem cell therapy manufacturing facilities, source of stem cells (allogenic and autologous), types of services offered (culture development, stem cell identification / validation, stem cell banking, cryopreservation, logistics, fill / finish and regulatory filings), scale of operation (preclinical, clinical and commercial), types of stem cells (adult, embryonic and induced pluripotent) and therapeutic area (oncology and non-oncology). In addition, the chapter presents a list of the in-house players involved in manufacturing of stem cell therapies.

Chapter 5 provides a detailed description on the regulatory landscape related to stem cells and cell therapies across various geographies, such as the North America (primarily the US), Europe and other regions. Further, it presents an analysis of the manufacturing facilities on the basis of certifications awarded (for contract manufacturing stem cell-based therapies) to individual sites by various regulatory bodies across the globe.

Chapter 6 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in North America. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 7 provides detailed profiles of some of the key players that are active in the stem cell contract manufacturing market in emerging regions such as Europe and Asia-Pacific. Each profile presents a brief overview of the company, financial information (if available), its contract service offerings highlighting the capabilities of stem cell therapy facilities, recent developments and an informed future outlook.

Chapter 8 features an elaborate analysis and discussion on the collaborations and partnerships that have been inked amongst players, since 2015. It includes brief descriptions of the various partnership models (including acquisition, distribution agreement, licensing agreement, manufacturing, product development / commercialization, product development and manufacturing, process development and manufacturing, process development, R&D agreements, service alliance and others) that have been adopted by stakeholders in this domain. It also includes analysis based on year of agreement, type of agreement, scale of operation, source of stem cells used, types of stem cells and location of companies entering the partnership. Further, the chapter features a world map representation of all the deals inked in this field, highlighting those that have been established within and across different continents.

Chapter 9 presents a detailed analysis to understand the relationship between the demand and supply in this field, comparing the presence of stem cell therapy developers and the availability / capability of contract manufacturers across different geographies. The chapter presents a list of stem cell therapies along with other details, such as stage of development, source of stem cell therapy and location of the developer.

Chapter 10 features an analysis of the global / regional capacity of contract manufacturers that are engaged in the manufacturing of stem cell therapy products. The analysis takes into consideration the individual development and manufacturing capacities of various stakeholders (small-sized, mid-sized, and large CMOs) in the market, using data from both secondary and primary research. The results of this analysis were used to establish an informed opinion on the stem cell therapy production capabilities of organizations across different types of organization (industry and non-industry), scale of operation (clinical and commercial), geographies (North America, EU, Asia Pacific and the rest of the world) and size of the organization (small-sized, mid-sized and large-sized organizations).

Chapter 11 features an illustrative view on the demand for stem cell therapies (both clinical and commercially available) in the market, offering an informed opinion on the required scale of supply (in terms of stem cell therapy manufacturing services). For the purpose of estimating the current clinical demand, we considered the active clinical studies of different types of stem cell therapies that have been registered since 2010. The data was analyzed on the basis of various parameters, such as number of annual clinical doses, trial location, leading industry / non-industry sponsors, and the enrolled patient population across different geographies. Further, in order to estimate the commercial demand, we considered the commercialized stem cell products, based on various parameters, such as target patient population, dosing frequency and dose strength.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of the stem cell contract manufacturing market till the year 2030. In order to provide details on the future opportunity, our projections have been segmented on the basis of [A] source of stem cells (autologous and allogenic), [B] types of stem cells (adult, embryonic and induced pluripotent), [C] size of contract service provider company (small-sized, mid-sized and large), [D] scale of operation (preclinical, clinical and commercial) and [E] key geographical regions (North America, Europe and Asia and rest of the world).

Chapter 13 features an analysis on the key performance indicators of service providers based on the information available for top-ten (based on the annual revenues generated in 2017)

Chapter 14 is a summary of the entire report. It provides the key takeaways and presents our independent opinion on the stem cell therapies contract manufacturing market, based on the research and analysis described in the previous chapters. It also provides a recap of some of the upcoming future trends, which, we believe, are likely to influence the growth of stem cell therapy contract manufacturing market.

Chapter 15 features the transcripts of interviews conducted with representatives from renowned organizations that are engaged in the stem cell therapy contract manufacturing domain. We have inputs from Arik Hasson (Executive VP Research and Development, Kadimastem), Brian Dattilo (Manager of Business Development, Waisman Biomanufacturing), David Mckenna (Professor and American Red Cross Chair in Transfusion Medicine, University of Minnesota), Fiona Bellot (Business Development Manager, Roslin Cell Therapies), Gilles Devillers (General Manager, Bio Elpida) and Mathilde Girard (Department Leader, Cell Therapy Innovation and Development, YposKesi).

Chapter 16 is an appendix that contains tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix that provides the list of companies and organizations mentioned in the report.

Read the full report: https://www.reportlinker.com/p05826166/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/stem-cell-therapy-contract-manufacturing-market-2019-2030-300953687.html

SOURCE Reportlinker

More here:
Stem Cell Therapy Contract Manufacturing Market, 2019-2030 - P&T Community

Arizona has been called "the wild, wild west" of regenerative medicine.

The Valley is one of the most popular places in the country for stem cell clinics. The new and controversial therapy is being marketed and practiced all over Phoenix and Scottsdale.

The less invasive procedure promises to heal pain, nearly anywhere in their body. It is advertised as effective, safe, and ethical, but outside experts and industry insiders say consumers need to do their research to avoid being exploited, and potentially spending thousands in cash on a worthless injection.

"IT HAS GREAT POTENTIAL"

The world of regenerative medicine is still being explored and developed.

"It actually gives you really good results," explained Dr. Matthew Hernandez, a naturopathic physician with Ethos.

"There's a lot of hope and promise, generally around the prospects for stem cells," said ASU Professor Emma Frow.

"Were still in the developmental stage. Stem cell therapy has been around for less than ten years. Thats new in medicine," said Dr. Steven Sorr, a naturopathic physician who runs Source of Health in Scottsdale.

"It encourages your own body to heal itself," said Janet McConnell, a 63-year-old bodybuilder who "had cartilage damage several years ago."

Instead of a surgery that would have derailed her competition training for months, she opted for injections.

"Three years ago, instead of the surgery, I had a PRP treatment," said McConnell. "It was very effective."

Years later, she returned to Dr. Hernandez for another round.

For most, Stem Cell and Platelet Rich Plasma (PRP) therapy is a mystery. "It's kind of controversial and experimental," said Matthew Riddle, Director of Sales for Celling Biosciences.

The treatments concentrate platelets or stem cells, usually from the patient's own blood. Experts say it is important to always ask the doctor or provider where the "growth factors" are coming from, because in order to ensure they are alive they should be coming from the patient's own blood, fat, or bone marrow. Otherwise, patients can receive "dead" stem cells, which are not nearly as effective.

"We are very adamant to use the patient's own cells," said Riddle, who uses a centrifuge to separate out the blood, saline and growth factors that will be re-injected. "When we inject that into an area, we are telling your body to go heal that spot," said Dr. Hernandez.

"Stem cell treatment is really about trying to take the stem cells out of your body and...inject them back into another part of your body, in order to try and heal whatever part of the body is suffering," said Professor Frow.

"IT'S THE NEW WAVE"

According to researchers, Scottsdale and Phoenix are two of the seven "hot spot" cities in the country.

Arizona State University professors Emma Frow and Dave Brafman spent years studying the industry , and mapping out dozens of clinics in the Valley. They believe there are many more, as some intentionally practice under the radar. "I don't believe right now that there is enough evidence to suggest that they work," said Professor Frow.

"They are unregulated, unproven and for-profit," added Professor Brafman.

The profits are plentiful. "There's cash involved, so this isn't covered by insurance," said Dr. Hernandez.

"PREYING ON PEOPLE'S PAIN"

The thousands in cash is one of many reasons the burgeoning industry is ripe for exploitation.

"The other piece too, it is it is new and upcoming," said Dr. Hernandez.

Many potential patients do not know the first thing about the procedure they are being sold, and doctors say many fall for sales tactics that are practiced at traveling seminars.

"They are preying on people's pain," said Dr. Sorr. "I think its really unethical and it upsets me."

Dr. Sorr believes the seminars are "a scam" that specifically targets an elderly clientele.

"They wine you and dine you. They go through a little dinner presentation and it is not the doctor, it's a marketing agency," he said.

The doctor told ABC15 he has had clients who have been duped, even after he told them they were not ideal candidates for stem cell or PRP therapy.

"It really broke my heart that he spent thousands upon thousands of dollars for something that was worthless.

"I don't agree with how they are done," said Dr. Hernandez. "They inject people and they get money. That's not practicing medicine, that is selling."

Both naturopathic physicians told ABC15 that some patients do not need the treatment, or will get subpar results from the injections. They say it is well known in the industry that some practices will continue to sell in order to reap the thousands in cash.

"ALL OF IT FALLS ON THE PATIENT"

Right now, there is little regulation or oversight of the industry in Arizona.

"Really all of it the falls on the patient, with very little recourse if things go wrong," said Dr. Emma Frow.

During the course of our investigation, ABC15 discovered the Arizona Medical Board and County Health Department do not take complaints or oversee the people performing injections. The federal government has also been slow to implement widespread regulation.

"The FDA has their hands tied," said Dr. Sorr. "There are too many people out there that are doing this that havent had the proper training, they dont have the right experience, the right tools and all that."

There are some larger regulations in Arizona, governing who can handle a needle and perform injections.

Unlike other industries though, including massage therapy, there is no board that checks on licensing or investigates complaints involving botched procedures or alleged fraud.

"The state medical boards, need to become a little bit more involved in sort of identifying, or responding to claims," said Professor Brafman.

"I don't think it would hurt to have it, for sure. At the end of the day it's about protecting the public," said Dr. Hernandez.

For thousands of Arizonans, like Janet McConnell, regenerative medicine has helped heal chronic pain. Before spending thousands thousands though, do your research. "Always get a second opinion," said Dr. Sorr.

"I think this is really a case of buyer beware, or consumer beware," said Professor Frow.

If you are planning on undergoing a stem cell or PRP treatment, click here for questions experts say you should always ask ahead of time.

See the article here:
Arizona the "wild west" of stem cell therapy; experts say promising therapy ripe for exploitation - ABC15 Arizona

NEW YORK and SHANGHAI, Nov. 6, 2019 /PRNewswire/ --Cellular Biomedicine Group Inc.(NASDAQ: CBMG) ("CBMG" or the "Company"), a biopharmaceutical firm engaged in the drug development of immunotherapies for cancer and stem cell therapies for degenerative diseases, today reported its financial results and business highlights for the third quarter of 2019.

"During the third quarter of 2019, we made great strides in both corporate and clinical progress. We started our U.S. expansion for research and clinical development in a new 22,000 square foot facility in Rockville, Maryland in October 2019. This milestone will allow us to foster strategic partnerships, develop new innovations and support continued development of CBMG's cell therapy-based immune-oncology assets that have shown promise in early proof-of-concept trials in China," said Tony (Bizuo) Liu, Chief Executive Officer for the Company.

"We also had continued progress on the clinical side, with the initiation of our Phase II clinical trial in China of AlloJoin therapy for knee osteoarthritis (KOA). Additionally, our autologous stem cell therapy program for KOA, ReJoin, was accepted by the NMPA in China to begin a Phase II clinical trial. We are excited about our regenerative medicine programs as we are currently the only company that has received two clinical trial acceptances for any stem cell program in China."

Mr. Liu continued, "Presentations of our pre-clinical and clinical data at upcoming medical conferences later this year will demonstrate continued focus on our immune-oncology pipeline and we are proud to provide an update of our commitment to cancer immunotherapy."

Third Quarter 2019 and Other Recent Corporate Developments

Upcoming Clinical and Preclinical Presentations:

Financial Results for the Third Quarter of 2019

Conference Call and Webcast InformationThe Company will host a conference call and webcast with the investment community on Wednesday, November 6th at 4:30 p.m. Eastern Time featuring remarks by Tony Liu, Executive Director, CEO and CFO of CBMG.

Live Call:

Toll-Free: 1-855-327-6838

International: 1-604-235-2082

Webcast:

http://public.viavid.com/index.php?id=136796

Replay:

Toll-Free: 1-844-512-2921

International: 1-412-317-6671

Conference ID: 10007976

(Available approximately two hours after the completion of the live call until 11:59 p.m. ET on November 20, 2019)

About Cellular Biomedicine GroupCellular Biomedicine Group, Inc. (NASDAQ: CBMG) develops proprietary cell therapies for the treatment of cancer and degenerative diseases. It conducts immuno-oncology and stem cell clinical trials in China using products from its integrated GMP laboratory. The Company's GMP facilities in China, consisting of twelve independent cell production lines, are designed and managed according to both China and U.S. GMP standards. Its Shanghai facility includes a "Joint Laboratory of Cell Therapy" with GE Healthcare and a "Joint Cell Therapy Technology Innovation and Application Center" with Thermo Fisher Scientific, which partnerships focus on improving manufacturing processes for cell therapies. CBMG currently has ongoing CAR-T Phase I clinical trials in China. The China NMPA (formerly CFDA) accepted the Company's IND application for a Phase II trial for AlloJoin, CBMG's "Off-the-Shelf" allogenic haMPC therapy for the treatment of Knee Osteoarthritis (KOA), and the Company's IND application for a Phase II trial for ReJoin autologous haMPC therapy for the treatment of KOA. CBMG is included in the broad-market Russell 3000 Index and the small-cap Russell 2000 Index, and the Loncar China BioPharma index. To learn more about CBMG, please visit http://www.cellbiomedgroup.com.

Forward-Looking StatementsStatements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts and may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include those regarding our ability to implement our plans, strategies and objectives for future operations, including regulatory approval of our IND applications, our plan to configure part of our Shanghai facility with GE Healthcare's FlexFactory platform, our ability to execute on our obligations under the terms of our licensing and collaboration arrangement with Novartis, our ability to execute on proposed new products, services or development thereof, results of our clinical research and development, regulatory infrastructure governing cell therapy and cellular biopharmaceuticals, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, our ability to seek intellectual property rights for our product candidates, competition in the industry in which we operate, overall market conditions, any statements or assumptions underlying any of the foregoing and other risks detailed from time to time in CBMG's reports filed with the Securities and Exchange Commission, Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

For more information, please contact:

Company Contact:Derrick C. LiHead of Strategy and Investor Relations, CBMGPhone: 917-717-0994Email: derrick.li@cellbiomedgroup.com

Investor Contact:Valter Pinto / Allison SossKCSA Strategic CommunicationsPhone: 212-896-1254 / 212-896-1267Email: cellbiomed@kcsa.com

CELLULAR BIOMEDICINE GROUP, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(UNAUDITED)

September 30,

December 31,

2019

2018

Assets

Cash and cash equivalents

$29,035,677

$52,812,880

Restricted cash

17,000,000

-

Accounts receivable, less allowance for doubtful accounts of nil and $94,868 as of September 30, 2019 and December 31, 2018, respectively

-

787

Other receivables

591,271

101,909

Prepaid expenses

1,589,479

1,692,135

Total current assets

48,216,427

54,607,711

Investments

240,000

240,000

Property, plant and equipment, net

19,856,287

15,193,761

Right of use

14,298,613

15,938,203

Goodwill

7,678,789

7,678,789

Intangibles, net

7,521,523

7,970,692

Long-term prepaid expenses and other assets

7,640,535

5,952,193

Total assets

$105,452,174

$107,581,349

Liabilities and Stockholders' Equity

Liabilities:

Short-term debt

$14,138,419

$-

Accounts payable

5,686,023

422,752

Accrued expenses

1,477,174

1,878,926

Taxes payable

28,625

28,950

Other current liabilities

4,526,594

5,710,578

Total current liabilities

25,856,835

8,041,206

Other non-current liabilities

12,545,245

14,321,751

Total liabilities

38,402,080

22,362,957

Stockholders' equity:

Preferred stock, par value $.001, 50,000,000 shares authorized; none issued and outstanding as of September 30, 2019 and December 31, 2018, respectively

-

-

Visit link:
Cellular Biomedicine Group Reports Third Quarter of 2019 Financial Results and Business Highlights - P&T Community

Dr Bright, who voluntarily surrendered his registration on August 31, was banned from reapplying for seven years.

He was also ordered to pay the costs of the Health Care Complaints Commission (HCCC), which filed the complaints against him in January.

Dr Bright founded Macquarie Stem Cells in Liverpool, which on its website spruiks its experimental treatments as "lead[ing] the way" and "our way of giving back to the community".

Dr Bright was referred to the HCCC by deputy state coroner Hugh Dillon in 2016 over the "preventable" and "unnecessary" death of an elderly patient after an experimental liposuction stem cell procedure to treat her dementia.

The coroner found the 75-year old died due to a "cluster of errors", including a failure to stop taking blood thinning medication prior to surgery, resulting in uncontrolled blood loss.

The tribunal agreed with Coroner Dillon that the treatment bore the hallmarks of "quack medicine".

It also accepted the evidence of Professor Colin Masters from the University of Melbourne, who said there was no evidence stem cell therapy for dementia patients was safe and it was "completely inappropriate and unethical" on a person who was frail, in poor health and in an advanced stage of dementia.

The tribunal found no proper therapeutic basis for Dr Bright administering the same stem cell treatment on a "very vulnerable" patient suffering bilateral vestibular deficiency, a condition where there is difficulty maintaining balance.

The tribunal accepted the patient - who was allegedly told by Dr Bright the procedure was "100 per cent safe" - has been adversely impacted.

The other complaints upheld related to Dr Bright's prescribing of peptides to three patients, including a woman with terminal motor neurone disease.

The tribunal found Dr Bright did not conduct a proper assessment on a patient before prescribing peptides and failed to take adequate steps to obtain informed consent, including an acknowledgement of the lack of clinical data proving the effectiveness of peptides and potential side effects.

Dr Bright's extensive self-prescribing of peptides was "improper and unethical", the tribunal found.

Dr Bright denied the allegations through his lawyers earlier in the year, but instructed his legal team to cease acting for him in August.

He did not attend the tribunal's hearing and did not respond to the orders it handed down.

Carrie Fellner is an investigative reporter for The Sydney Morning Herald.

See the original post:
Surgeon banned over 'quack' procedures and 'reckless disregard' for safety - Sydney Morning Herald

Former Google CEO Eric Schmidt has a vision for healthcare.

He explained it on a recent episode of the podcast Theory and Practice, which focuses on the intersection of biology and computer science. The podcast is produced by Google AI and the venture arm GV, which was formerly known as Google Ventures.

Schmidt, a billionaire who studied electrical engineering at Princeton University, was Googles CEO for a decade and later served as executive chairman. He left that role at Googles parent company, Alphabet, in 2018.

Schmidt has long held beliefs about the important role of big data and data sharing, he said. Data sharing has faced obstacles in healthcare, where the privacy of personal health data is a big concern.

Schmidt said he believed that better data access and sharing would improve healthcare.

If you look at the medical system in America, it was never designed in a way that you and I would sort of agree as rational. The incentives are misaligned; the databases are poor, Schmidt told the cohosts Anthony Philippakis, a venture partner at GV, and Alex Wiltschko, a senior research scientist with Google AI.

I believe that because of the gains in machine learning and data analysis, we have an opportunity to rethink some of those underlying assumptions, he added.

Because of the disjointed nature of the US healthcare system, Schmidt said that all medical data should be in one place that is easy for the doctor and patient to access.

When I go to the doctor, I want to give them a login and a password for me, and when they log in, I want them to see all of my medical data from everywhere, Schmidt said.

As Schmidt said in the podcast episode that, oftentimes, when a patient has to have multiple tests done by different specialists, the medical information is not shared between their systems. This is just one example of the disconnected communications that Schmidt says could easily be fixed.

Another important point to fix is making large amounts of health data available for research purposes. Schmidt said the privacy issue could be resolved by allowing patients to opt out of data collection. Otherwise, that data is, by custom, made available for research purposes to make the system stronger, he said.

Schmidt said that a key step would be to put all medical data on the cloud, where it can more easily be accessed and analyzed.

Right now, the majority of medical data is not even in the electronic-health-record system, its in other systems that are sitting around in the hospital, Schmidt said. But the work is underway, and all EHRs will be cloud-based quite soon.

For Schmidt, cloud computing is beneficial in healthcare because its often less expensive and can support the massive amounts of data the industry constantly produces.

With cloud computing, you know the system wont fall over, he said.

But Schmidt doesnt just want to store electronic health records on the cloud. He also wants to collect other clinical data from hospital systems and eventually all clinical data in the healthcare industry.

Wed have a much fuller picture of whats going on in a medical care setting, and that would allow us to do better data analytics, better prediction and better healthcare, Schmidt said.

Schmidt said he believed healthcare systems would be quick to move to the cloud if it could prove to be beneficial for the patient and doctor by saving time and peoples lives.

With access to more patient data, Schmidt believes computers can help the healthcare system by providing more accurate medical diagnoses for a larger group of people.

Big data can provide better predictive analytics, he said. He said deep data science could be used to help doctors make better decisions.

I want a computer to be able to say, Heres your history; heres what we think is going on, and give advice using deep data science, doing deep predictive analytics, and AI in general to predict what the doctor should do next, Schmidt said. I think this will lead to a revolution in healthcare in terms of productivity and, most important, my health and your health and everyones.

Link:
Global Canine Stem Cell Therapy Market 2019, Trend, CAGR Status, Growth, Analysis and Forecast to 2024 - Techi Labs

The globalViral Inactivation Marketis carefully researched in the report while largely concentrating on top players and their business tactics, geographical expansion, market segments, competitive landscape, manufacturing, and pricing and cost structures. Each section of the research study is specially prepared to explore key aspects of the global Viral Inactivation market. For instance, the market dynamics section digs deep into the drivers, restraints, trends, and opportunities of the global Viral Inactivation market.

With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Viral Inactivation market. We have also focused on SWOT, PESTLE, and Porters Five Forces analyses of the global Viral Inactivation market.

Leading companies operating in the Global Viral Inactivation market profiled in the report are:

Danaher

Merck

Parker Hannifin

Sartorius

SGS

Charles River Laboratories International

Clean Cells

Rad Source Technologies

Texcell

Viral Inactivated Plasma Systems

Wuxi Pharmatech (Cayman)

Get a Sample Copy of the Report:

https://www.marketinsightsreports.com/reports/01011041155/global-viral-inactivation-market-size-status-and-forecast-2019-2025/inquiry?Mode=88

Market Segment by Type, covers:Kits and Reagents

Services

Viral Inactivation Systems and Accessories

Market Segment by Applications, covers:Blood and Blood Products

Cellular and Gene Therapy Products

Stem Cell Products

Tissue and Tissue Products

Vaccines and Therapeutics

Regional Analysis For Viral Inactivation Market:

North America (United States, Canada and Mexico)Europe (Germany, France, UK, Russia and Italy)Asia-Pacific (China, Japan, Korea, India and Southeast Asia)South America (Brazil, Argentina, Colombia etc.)Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Inquire For Discount:

https://www.marketinsightsreports.com/reports/01011041155/global-viral-inactivation-market-size-status-and-forecast-2019-2025/discount?Mode=88

-Comprehensive assessment of all opportunities and risk in the Viral Inactivation market.

-Viral Inactivation market recent innovations and major events.

-Detailed study of business strategies for growth of the Viral Inactivation market-leading players.

-Conclusive study about the growth plot of Viral Inactivation market for forthcoming years.

-In-depth understanding of Viral Inactivation market-particular drivers, constraints and major micro markets.

-Favourable impression inside vital technological and market latest trends striking the Viral Inactivation market.

-Key Strategic Developments: The study also includes the key strategic developments of the market, comprising R&D, new product launch, M&A, agreements, collaborations, partnerships, joint ventures, and regional growth of the leading competitors operating in the market on a global and regional scale.

-Key Market Features: The report evaluated key market features, including revenue, price, capacity, capacity utilization rate, gross, production, production rate, consumption, import/export, supply/demand, cost, market share, CAGR, and gross margin. In addition, the study offers a comprehensive study of the key market dynamics and their latest trends, along with pertinent market segments and sub-segments.

-Analytical Tools: The Global Viral Inactivation Market report includes the accurately studied and assessed data of the key industry players and their scope in the market by means of a number of analytical tools. The analytical tools such as Porters five forces analysis, SWOT analysis, feasibility study, and investment return analysis have been used to analyse the growth of the key players operating in the market.

Browse Full Report at:

https://www.marketinsightsreports.com/reports/01011041155/global-viral-inactivation-market-size-status-and-forecast-2019-2025?Mode=88

ABOUT US:

MarketInsightsReports provides syndicated market research on industry verticals including Healthcare, Information and Communication Technology (ICT), Technology and Media, Chemicals, Materials, Energy, Heavy Industry, etc. MarketInsightsReports provides global and regional market intelligence coverage, a 360-degree market view which includes statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations

Irfan Tamboli (Head of Sales) Market Insights Reports

Phone: + 1704 266 3234 | +91-750-707-8687

sales@marketinsightsreports.com | irfan@marketinsightsreports.com

Excerpt from:
Viral Inactivation Market Global Research and Study by Experts 2019 to 2025 - The Market Publicist

The global stem cell banking industry is estimated to grow from USD 5.68 billion 2017 to USD 9.87 billion by the end of 2024 showing a growth rate of 8.21%.

Click here for more information @https://www.reportocean.com/industry-verticals/details?report_id=21506

The new report has been added to the reportocean.com depository that provide management with accurate, relevant, valid, and current information related to Stem Cell Banking Market. The Stem Cell Banking industry report 2019, help Stem Cell Banking Companies or new entrants in the Stem Cell Banking industry to stay competitive and avoid the risk of poor decisions based on unsound information.

The listed Stem Cell Banking study helps the marketing managers to develop an understanding about the suppliers, consumers, channel partners, competitors, Stem Cell Banking growth outlook, industry trends, key strategies (Stem Cell Banking industry mergers & acquisitions, collaboration, Partnership, etc.), and new product/service developments. Also, the study does focus on market share of Stem Cell Banking major players and market size value.

Moreover, the Stem Cell Banking market research report 2019 helps to identify Stem Cell Banking market year-on-year growth in global, regional, and country level, along with various possible Stem Cell Banking industry segments/verticals. The Stem Cell Banking report provides you market size data for historical, present, and forecast years along with the CAGR for regional, country and Stem Cell Banking industry segments.

To know the Key player profile in the report, send a sample request athttps://www.reportocean.com/industry-verticals/sample-request?report_id=21506

The major region/countries coverage in our reports are:

North America (United States, Canada)

Europe (Germany, UK, France, Italy, Spain, Belgium, Russia, Netherlands, Rest of Europe)

Asia-Pacific (China, Japan, India, Korea, Singapore, Malaysia, Indonesia, Thailand, Philippines, Rest of the Asia-Pacific)

Latin America (Mexico, Brazil, Argentina, Rest of LATAM)

Middle East and Africa (UAE, Saudi Arabia, South Africa, Rest of MEA)

The country-level information can be provided for other countries also, as the scope is not limited to above mention countries only, it may be varying upon the scope of the market.

The Global Stem Cell Banking report helps you with the:

Recognizing potential opportunities and problems related to Stem Cell Banking market

Investing tactics

Planning and execution of the marketing campaign

Identify promising new partners and suppliers

Identify the Target market

Produce, examine, and improve market actions

Clear understanding of the responsiveness of different segments in the Stem Cell Banking industry

The report consists of detailed insight for the Global Stem Cell Banking market that includes realistic overview of the industry, consist of Stem Cell Banking manufacturers data, i.e. financial overview, recent developments, gross profit, business distribution, and product benchmarking, etc., Moreover, report also talk about SWOT analysis, mega trends, company profile, drivers and restrain factors, gap analysis, investment opportunity, forecast market size, Porters Five Models, services and products, socioeconomic factors, government regulation in Global Stem Cell Banking industry.

The report, in short, is very rigorously prepared and is as authentic and reliable as it can be.

For getting a better understanding of the segments, click herehttps://www.reportocean.com/industry-verticals/details?report_id=21506

Important Coverage of the Report:

The Stem Cell Banking market has been segmented on the bases of different types/applications/channels/end users to provide deep down-market insight for the historic, current, and future market trends. In fact, the report produces a very careful analysis to provide a comprehensive view of the market after considering all commissions and omissions.

1) Stem Cell Banking Market Overview

a. Market Definition

b. Industry snapshot

c. Ecosystem analysis

2) Stem Cell Banking Market Competitive Landscape

a. Market Share Analysis

b. Major Growth Strategy in the Global Stem Cell Banking Market

c. Competitive Benchmarking

d. Leading Player in terms of Number of Developments in the Market

3) Stem Cell Banking Major Players Company Profiles

a. Revenue and Gross profit 2016-2018

b. Business Revenue by Region

c. Business Segments Revenue

d. Business Profile

e. Products/Service offering

f. Key Strategy

g. SWOT Analysis

4) Global Stem Cell Banking Market Segmentation (Market Estimates and Forecast 2016-2026*) USD Million

a. Industry Level Segment

Market Estimates and Forecast, by Global, 2016-2026

Market Estimates and Forecast, by Region, 2016-2026

Market Estimates and Forecast, by Country, 2016-2026

b. Channel level Segment

Market Estimates and Forecast, by Global, 2016-2026

Market Estimates and Forecast, by Region, 2016-2026

Market Estimates and Forecast, by Country, 2016-2026

c. Product Type Segment

Market Estimates and Forecast, by Global, 2016-2026

Market Estimates and Forecast, by Region, 2016-2026

Market Estimates and Forecast, by Country, 2016-2026

d. End-User Segment

Market Estimates and Forecast, by Global, 2016-2026

Market Estimates and Forecast, by Region, 2016-2026

Market Estimates and Forecast, by Country, 2016-2026

e. Others Segment

Market Estimates and Forecast, by Global, 2016-2026

Market Estimates and Forecast, by Region, 2016-2026

Market Estimates and Forecast, by Country, 2016-2026

5) Market Dynamic

a. Drivers

b. Restrain

c. Opportunity

d. Trends

6) Market Factor Analysis

a. Supply/value chain analysis

b. Porters five forces

c. Regulatory Scenario*

7) Conclusion

For getting a better understanding of the segments, send us a Sample Request athttps://www.reportocean.com/industry-verticals/sample-request?report_id=21506

Parameters for the Study:

The comprehensive study has been prepared carefully by considering all possible parameters. Some of these were

Factors that impact the market growth

Consumers options and preferences

Technological environment and facilitators

Perceived challenges and constraints

Law and regulations analysis

Opportunities

Consumer spending dynamics and trends

Other developments

Follow us on:

Facebook: https://www.facebook.com/reportocean

Twitter: https://twitter.com/reportocean

LinkedIn: https://in.linkedin.com/company/reportocean

Contact: +1 888 212 3539 (US) +91-9997112116 (Outside US)Contact Person: Sandeep SinghEmail:sales@reportocean.com

Continued here:
Market Segmentation: Global Stem Cell Banking Market Analysis; What are the Limitation of the Market? How can these Limitation be Overcome? -...

Fish that adapted to survive in the frigid waters of Antarctica offer a gateway to better understand the genetics of human aging, but the fish are being threatened by climate change, says University of Oregon biologist John Postlethwait.

Thats the message he will deliver Nov. 13 in a Quack Chats pub talk at Eugenes Downtown Athletic Club, 999 Willamette St. The talk will begin at 6 p.m. in the third-floors Ax Billy Grill.

These are remarkably beautiful and complex animals, said Postlethwait, a professor emeritus and member of the UOs Institute of Neuroscience. Climate change is threatening them. We need to study them more before they become extinct or try to change the conditions so that we limit the effects of climate change and maybe reduce the chances of extinction.

Postlethwait traveled five times to Antarctica between 2008 and 2018 with funding from the National Institutes of Health and National Science Foundation. He has studied dragonfish and icefish, primarily the low bone mineralization that evolved in bottom-dwelling icefish to allow them to increase their buoyancy and rise in the water column to feed.

That adaptation of turning off certain genes to become less dense in the absence of swim bladders think lungs in humans began about 30 million years ago as Antarctic waters cooled. Todays seawater temperature there hovers just below the freezing point of fresh water.

The bones in these fish look like old peoples bones, said Postlethwait, who ran a marathon in Antarctica during one of his research trips. As people age, they turn off or turn down the genes that are important for maintaining bone health.

In his talk, Dragons and Icefish: Surviving Frigid Antarctic Seas, hell detail the biology and molecular genetics of these Antarctic fish and how they hold genetic clues that may be useful for understanding anemia, oversized hearts and low bone-mineral density in humans.

The potential human health payoff was boosted earlier this year when an international team that included Postlethwait and six other UO researchers published the complete genome sequence for Antarctic blackfin icefish.

To learn more about upcoming Quack Chats, see the Quack Chats section on Around the O. A general description of Quack Chats and a calendar of additional Quack Chats and associated public events also can be found on the UOs Quack Chats website.

By Jim Barlow, University Communications

Read more from the original source:
Pub talk will explore links between icefish and human aging - AroundtheO

A team of UBC researchers used advanced techniques in microscopy and chemical profiling to determine that cannabis flowers with the biggest hairs produce the most CBD, THC, and fragrance-emitting terpenes.

The research was the first to detail the structures and chemical-creating abilities of the three kinds of frostlike pot hairsstalked, sessile, and bulbouscalled glandular trichomes.

Finola, a fast-flowering hemp variety of Cannabis sativa, was used by the team, which included researchers from UBC's Wine Research Centre and the Michael Smith Laboratories.

Teagen Quilichini, the study's co-lead author and a postdoctoral fellow with the botany department, said in an October 28 UBC news release that the study is an important beginning for subsequent research.

Despite its high economic value, our understanding of the biology of the cannabis plant is still in its infancy due to restricted legal access, Quilichinisaid. Trichomes are the biochemical factories of the cannabis plant and this study is the foundation for understanding how they make and store their valuable products.

The paper"Cannabis glandular trichomes alter morphology and metabolite content during flower maturation"appeared in the August 30 edition of the Plant Journal.

Anne Lacey Samuels, a botany professor and principal investigator for the study, said in the release that there could be many downstream benefits of the research.

We found a treasure trove of genes that support the production of cannabinoids and terpenes. With further investigation, this could be used to produce desirable traits like more productive marijuana strains or strains with specific cannabinoid and terpene profiles using molecular genetics and conventional breeding techniques.

The UBC team determined under ultraviolet light that the stalked trichomes glowed blue and had large, distinctive secretory discs of cells that looked like microscopic mushrooms or hamburgers.

We saw that stalked glandular trichomes have expanded 'cellular factories' to make more cannabinoids and fragrant terpenes, co-lead author Sam Livingston said in the release. We also found that they grow from sessile-like precursors and undergo a dramatic shift during development that can be visualized using new microscopy tools."

Livingston, a botany department PhD candidate, noted thatUV lightmight be used todetermine flowers' trichome maturity so growers would know the best times to harvest.

Read more here:
UBC cannabis researchers find that "frosty" flowers mean potent pot - Straight.com

SALT LAKE CITY, Nov. 07, 2019 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (MYGN), a leader in molecular diagnostics and precision medicine, announced today that Bryan Riggsbee, CFO, is scheduled to present at the Stephens Nashville Investment Conference at 12:15 p.m. EST on November 13, 2019, in Nashville.

The presentation will be available to interested parties through a live audio webcast accessible through a link in the investor information section of Myriads website at http://www.myriad.com.

About Myriad GeneticsMyriad Genetics, Inc., is a leading precision medicine company dedicated to being a trusted advisor transforming patient lives worldwide with pioneering molecular diagnostics. Myriad discovers and commercializes molecular diagnostic tests that: determine the risk of developing disease, accurately diagnose disease, assess the risk of disease progression, and guide treatment decisions across six major medical specialties where molecular diagnostics can significantly improve patient care and lower healthcare costs. Myriad is focused on five critical success factors: building upon a solid hereditary cancer foundation, growing new product volume, expanding reimbursement coverage for new products, increasing RNA kit revenue internationally and improving profitability with Elevate 2020. For more information on how Myriad is making a difference, please visit the Company's website: http://www.myriad.com.

Myriad, the Myriad logo, BART, BRACAnalysis, Colaris, Colaris AP, myPath, myRisk, Myriad myRisk, myRisk Hereditary Cancer, myChoice, myPlan, BRACAnalysis CDx, Tumor BRACAnalysis CDx, myChoice HRD, EndoPredict, Vectra, GeneSight, riskScore Prolaris, ForeSight and Prequel are trademarks or registered trademarks of Myriad Genetics, Inc. or its wholly owned subsidiaries in the United States and foreign countries. MYGN-F, MYGN-G.

Excerpt from:
Myriad Genetics to Present at the 2019 Stephens Nashville Investment Conference - Yahoo Finance

Q&A

Penn's Kiran Musunuru talks to us about the technology that has been both praised and criticized for its ability to alter human DNA and potentially cure disease.

Kiran Musunuru is an associate professor of medicine in genetics in the Perelman School of Medicine at the University of Pennsylvania. / Courtesy

CRISPR, the technology being used to edit genes in humans, remains polarizing. On one end, detractors argue that using the technology for certain purposes, like performing gene editing on embryos, is not only dangerous but unethical. On the other end, proponents say CRISPR has the potential to revolutionize human health, and early data shows they might be right. Despite a medical community that is still split on the issue, researchers in the U.S. are kicking tests of the technology into high gear. Several clinical trials have launched in the U.S. testing CRISPRs ability to treat various diseases.

NextHealth PHL spoke with Kiran Musunuru, an associate professor of medicine in genetics at the Perelman School of Medicine at the University of Pennsylvania about the true potential of CRISPR technology and how we can expect it to evolve in the future.

NextHealth PHL: What exactly is CRISPR?Musunru: CRISPR is sort of a catch-all term that covers a variety of technologies. If youre saying CRISPR, youre referring to a broad set of tools that may do it in different ways but are all intended to do a form of gene editing or genome editing.

How do basic CRISPR technologies work?The simplest form of CRISPR, what I call version 1.0, is the original standard CRISPR that most laboratories and companies interested in developing new therapies use. It is a two-component system. There is a protein and an RNA molecule thats about 100 bases in length. The protein and the RNA molecule come together to create what well call a molecular machine and the purpose of this molecular machine is to scan across any DNA molecule it encounters. So if you put the CRISPR-Cas9 into the nucleus of a human cell, this molecular machine will scan the entire genome.

The machine has two key functions built into it; the first is a GPS function. When you change the first 20 bases in a DNA length (the first 20 bases is basically the address) to whatever address you want, the GPS function makes the machine go through the entire genome and find the sequence that matches the address. The second function of this machine is to protect the genome, like a search-and-destroy function. You put in the address, it goes to that matching place in the genome and then it makes a cut in the DNA.

Cutting the DNA is actually a bad thing but the cells have ways to try to fix that break, and the actual editing is a result of the cell trying to fix that break in the DNA, not from CRISPR itself, interestingly enough.

How does CRISPR turn a break in someones DNA into a good thing?There are a few ways this can happen. The safest thing you can do is to break a gene or turn off a gene. The metaphor I like to use is to think of the whole genome as a book, and each chromosome in the genome is a chapter in the book, and each gene is a paragraph in the chapter. Together, it all has a meaning. But lets say you had to turn off a gene, the equivalent of making that break in the DNA would be like tearing the page through that paragraph. So, the simplest thing the cell can do and will try to do is to simply tape that tear back up. But as you can imagine, sometimes you tape it back up and its fine, the paragraph is still legible and the meaning is still there, and it eventually heals and functions like it did before. But in this case, thats actually not what you want. The outcome that you want with CRISPR is that you actually want to turn off the gene, not to rip it and make it the way it was before.

What has to happen is when you make the tear, the tear is so rough, you get those jagged edges and you try to tape it up but it doesnt quite fit, the letters dont quite match up. You tape it up as best as you can but its illegible, some letters are lost, and the meaning of the paragraph is lost. Thats exactly what happens with gene editing, the cell tries to repair that break in the DNA, doesnt get it quite right, and loses some bases and that messes up the gene and turns it off.

However, in this scenario, you cant really control what happens. All you can hope for is that that tear you make is going to mess up the gene and thats okay if all youre trying to do is turn it off. Most of the trials underway now are about turning off the gene, and theyre all taking advantage of the fact that its relatively easy to mess up genes and turn off genes. Just like tearing a page its crude, but its effective.

Theres CRISPR 1.0, this first generation of the technology thats not very precise and is a bit arduous. What are the newest forms of CRISPR and how are they better than earlier versions of the technology? There is a newer form of the technology called base editing that keeps the GPS function intact but removes the cutting function. In place of the cutting function, it attaches another machine onto CRISPR and makes chemical modifications in certain areas. This version of CRISPR is more like a search and replace. CRISPR provides the search but then another machine attached to it is doing the replacing. With base editing you can make more precise changes, but only rarely will it make exactly the type of change you want.

The latest form of CRISPR is called prime editing, and we still dont have a good sense of how well it works because its so new. Whats tantalizing is that it looks like it can turn CRISPR into a precise word processor or an eraser that allows you to erase a letter and put in a new letter. CRISPR is very much a wave of technology, and as it gets better, its going to allow us to do more and more powerful things.

There are some extreme ideas about what CRISPR can do. Some believe scientists can use the technology to alter hair or eye color or give patients superhuman athletic or intellectual abilities. Is any of this possible with CRISPR?It depends on what traits youre talking about changing. Since eye color and hair color are controlled by single genes, you could possibly make a single gene change with CRISPR. The problem is, how do you get CRISPR to go where it needs to go to change your hair or eye color? How do you get it into all your hair follicles or through all the cells in your eye? It might be a simpler change to make, but it might not be easy to do in a live adult. Scientists have now edited human embryos, resulting in live-born people. Theres been a lot of ethical debate about whether thats a good thing. If you want to change something like hair color in a single cell embryo made through in-vitro fertilization, thats a bit different and might not be as difficult.

There are some very complicated things, like intelligence or athletic ability, that are not going to be easy to change. Youd probably have to change hundreds of genes, and thats not going to happen anytime soon. With CRISPR as it is now, maybe you can change one gene; maybe if you really work at it you can change two genes, but hundreds of genes? Youre not going to be able to do that with CRISPR anytime soon.

What has CRISPR been used to treat so far and what could it be used for in the future?There are multiple trials underway to treat rare liver disorders. More recently CRISPR has been used in clinical trials at Penn where at least three patients have been dosed using CAR T immunotherapy. In this case, theyre trying to make patients cells more effective at fighting cancer. But again, that editing is being done outside the body.

There are some things that seem like they would be difficult to treat, but if its the right type of disease and you can get CRISPR to where you need it to go, it might work. One example is in sickle cell disease. The cells that you need to fix in sickle cell disease are in the bone marrow. Fortunately, bone marrow is relatively straight forward to work with. You take the cells out and edit them with some form of CRISPR outside of the body and then put them back in.

Something like cystic fibrosis would be much harder because it affects the entire surface of potentially multiple organs inside the body. Its much harder to deliver CRISPR to all of those places in the body.

There are two other clinical trials that have started in the U.S. One is from a company called CRISPR Therapeutics to treat sickle cell disease and similar blood disorders. Theres another trial underway to treat a genetic form of blindness and this editing would actually happen inside the body.

Excerpt from:
Q&A: Everything You Need to Know About the Future of CRISPR-Cas9 - Philadelphia magazine

About the role

The Neuroecology Research Laboratory lies at the intersection of two major fields of biology (Neurobiology: the study of the nervous system, and Ecology: the study of the interaction between living organisms and their environment). Neuroecology bridges the gap between our knowledge of the neural bases of animal behaviour and the consequences of that behaviour in the context of an animal's habitat and ecology.

We are seeking a Postdoctoral Researcher in Neuroecology to join our team within the Department of Physiology, Anatomy and Microbiology (PAM), School of Life Sciences at La Trobe University, Victoria, Australia.

We use innovative neurobiological techniques such as molecular genetics, bioimaging, electrophysiology, anatomy and behaviour to examine how key elements of the physical environment such as light, sound, odours, and electromagnetic fields are detected and processed by the peripheral and central nervous systems and how this influences their behaviour. The ability to perceive these environmental cues is critical to the survival of each species. Model indicator species are used to assess how ecosystems may be faring in light of climate variability and habitat loss or degradation.

Skills & Experience

Benefits

Please click on this link for a full list of Benefits http://www.latrobe.edu.au/jobs/working/benefits

How to Apply

Closing date: 11pm Sunday 8th December 2019

Position Enquiries: Prof Shaun Collin, TEL: +61 (0)3 9479-3671 Email: s.collin@latrobe.edu.au

Position Description below:

PD Level A Postdoc Neuroecology.pdf

Please submit an online application ONLY and include the following documents:

Please scroll down to apply.

La Trobe University is an Equal Opportunity Employer.

All La Trobe University employees are bound by the Working with Children Act 2005. If you are successful, you will be required to hold a valid Victorian Employee Working with Children Check prior to commencement.

For further enquiries on how to apply for this role, please contact Recruitment Partner Justin Bolton on +61 (0)3 9479 1073

To apply and to view position description please visit http://www.latrobe.edu.au/jobs and search for job number 559000 under current vacancies.

About La Trobe

La Trobe University's success is driven by people who are committed to making a difference. They are creative and highly motivated, pursue new ideas and create knowledge. La Trobe is one of Australia's research leaders, and the largest provider of higher education to regional Victoria. La Trobe University turned 50 in 2017, and over the half century of its existence it has established a reputation as an innovative and accessible university, willing to take risks and take on challenges. Our teaching and research address some of the most significant issues of our time and we're passionate about driving change through operational excellence to benefit the communities we serve.

See original here:
Postdoctoral Researcher, Neuroecology - The Conversation AU

The Prize awarded by the Infosys Science Foundation celebrates the success of the recipients in science and research by recognising their achievements in 6 categories.

Infosys Science Foundation (ISF) on Thursday announced the winners of the Infosys Prize 2019 in six categories - Engineering and Computer Sciences, Humanities, Life Sciences, Mathematical Sciences, Physical Sciences and Social Sciences. The Prize celebrates the success of the recipients in science and research by recognising their achievements in each category. The prize for each category comprises a pure gold medal, a citation and a prize purse of USD 100,000 (or its equivalent in Rupees) this year.

A panel of accomplished jurors comprising renowned scholars and professors shortlisted the winners of Infosys Prize 2019 from 196 nominations. With a history of awarding some of the best talent, who have earned prestigious international honours like Fields Medal and the Nobel Memorial Prize more recently, the ISF believes that this years winners too will leave an indelible impression in their domains. The Infosys Prize not only recognises these outstanding researchers and celebrates their achievements, but in doing so, creates role models who will encourage young minds to explore science as a career option.

S. D. Shibulal, Co-founder, Infosys Limited and President of the Infosys Science Foundation, said, The Infosys Prize continues to recognise exemplary work in scientific research and enquiry. Many Infosys Prize laureates have gone on to contribute significantly in key areas like healthcare, genetics, climate science, astronomy and poverty alleviation, amongst other things. Their work has immediate implications for the human race and the planet. We hope it catalyses social development.

Elaborating on the importance of fundamental research at the event, N. R. Narayana Murthy, Founder Infosys, Trustee Infosys Science Foundation, said, We should start helping our youngsters pursue fundamental research enthusiastically. They should be encouraged and equipped to become contributors to solving huge problems that confront us every day. I want India to be a place where discovery and invention happen every month.

Winners of the Infosys Prize 2019 in the six categories are:

Engineering and Computer Science

The Infosys Prize 2019 for Engineering and Computer Science is awarded to Sunita Sarawagi, Institute Chair Professor, Computer Science and Engineering, Indian Institute of Technology, Bombay for her research in databases, data mining, machine learning and natural language processing, and for important applications of these research techniques. The prize recognises her pioneering work in developing information extraction techniques for unstructured data.

Humanities

The Infosys Prize 2019 for Humanities is awarded to Manu V. Devadevan, Assistant Professor, School of Humanities and Social Sciences, Indian Institute of Technology, Mandi for his original and wide-ranging work on pre-modern south India. He critically reinterprets much of the conventional wisdom about the cultural, religious and social history of the Deccan and south India.

Life Sciences

The Infosys Prize 2019 for Life Sciences is awarded to Manjula Reddy, Chief Scientist, Centre for Cellular and Molecular Biology (CCMB), Hyderabad for her groundbreaking discoveries concerning the structure of cell walls in bacteria. Dr. Reddy and her colleagues have revealed critical steps of cell wall growth that are fundamental for understanding bacterial biology.This work could potentially help in creating a new class of antibiotics to combat antibiotic resistant microbes.

Mathematical Sciences

The Infosys Prize 2019 for Mathematical Sciences is awarded to Siddhartha Mishra, Professor, Department of Mathematics, ETH Zrich, for his outstanding contributions to Applied Mathematics, particularly for designing numerical tools for solving problems in the real world. Prof. Mishra's work has been used in climate models, in astrophysics, aerodynamics, and plasma physics.He has produced codes for complicated realistic problems such as tsunamis generated by rock slides, and waves in the solar atmosphere.

Physical Sciences

The Infosys Prize 2019 for Physical Sciences is awarded to G. Mugesh, Professor, Department of Inorganic and Physical Chemistry, Indian Institute of Science (IISc), Bengaluru for his seminal work on the chemical synthesis of small molecules and nanomaterials for biomedical applications. His work has contributed to the understanding of the role of trace elements, selenium and iodine, in thyroid hormone activation and metabolism, and this research has led to major medical advances.

Social Sciences

The Infosys Prize 2019 for Social Sciences is awarded to Anand Pandian, Professor, Department of Anthropology, Krieger School of Arts & Sciences, Johns Hopkins University for his imaginative work on ethics, selfhood and the creative process. Prof. Pandian's research encompasses several themes such as cinema, public culture, ecology, nature and the theory and methods of anthropology.

See the original post here:
Data researcher to molecular scientist: List of winners of the 11th Infosys Prize 2019 - The News Minute